How to treat severe infections in critically ill neutropenic patients?

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Zafrani, Lara ^a   Azoulay, Elie ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CASPOFUNGIN; CEFEPIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; DAPTOMYCIN; DOBUTAMINE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIPENEM; IMMUNOGLOBULIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; NORADRENALIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE; ANTIINFECTIVE AGENT;

ACUTE RESPIRATORY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ALLOIMMUNIZATION; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; BACTEREMIA; BLOOD CULTURE; CATHETER INFECTION; CATHETER REMOVAL; CELLULITIS; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRITICALLY ILL PATIENT; CYTOMEGALOVIRUS INFECTION; DRUG CHOICE; DRUG INDICATION; FEBRILE NEUTROPENIA; FLUID RESUSCITATION; GRANULOCYTE TRANSFUSION; HISTOPATHOLOGY; HUMAN; INFECTION; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LUNG ASPERGILLOSIS; MYCOSIS; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; NONINVASIVE VENTILATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK; THORAX RADIOGRAPHY; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT DURATION; BACTERIAL INFECTIONS; CRITICAL ILLNESS; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; INTENSIVE CARE; MICROBIOLOGY; MYCOSES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; IMMUNOCOMPROMISED HOST; INTENSIVE CARE UNITS; MYCOSES; NEUTROPENIA;

EID: 84922235457     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-512     Document Type: Review

References (74)

1. Brenner H, Gondos A, Arndt V: Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol 2007,25(22):3274-3280. 10.1200/JCO.2007.11.3431.
2. Azoulay E: Pulmonary infiltrates in patients with malignancies: why and how neutropenia influences clinical reasoning. Eur Respir J 2009,33(1):6-8. 10.1183/09031936.00164208.
3. Viscoli C, Varnier O, Machetti M: Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005,40(Suppl 4):S240-245.
4. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011,52(4):e56-93. 10.1093/cid/cir073.
5. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, Ramsey SD: Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013,31(6):794-810. 10.1200/JCO.2012.45.8661.
6. Labelle AJ, Micek ST, Roubinian N, Kollef MH: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008,36(11):2967-2972. 10.1097/CCM.0b013e31818b3477.
7. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000,118(1):146-155. 10.1378/chest.118.1.146.
8. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW: Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003,37(6):745-751. 10.1086/377200.
9. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011,52(4):427-431. 10.1093/cid/ciq147.
10. Penack O, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Massenkeil G, Hentrich M, Salwender H, Wolf HH, Ostermann H: Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Ann Oncol 2011,22(5):1019-1029. 10.1093/annonc/mdq442.
11. Peacock JE, Herrington DA, Wade JC, Lazarus HM, Reed MD, Sinclair JW, Haverstock DC, Kowalsky SF, Hurd DD, Cushing DA, Harman CP, Donowitz GR: Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med 2002,137(2):77-87. 10.7326/0003-4819-137-2-200207160-00005.
12. Bliziotis IA, Michalopoulos A, Kasiakou SK, Samonis G, Christodoulou C, Chrysanthopoulou S, Falagas ME: Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2005,80(9):1146-1156. 10.4065/80.9.1146.
13. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013,39(2):165-228. 10.1007/s00134-012-2769-8.
14. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, Lemiale V, Seguin A, Darmon M, Schlemmer B, Azoulay E: Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012,40(1):43-49. 10.1097/CCM.0b013e31822b50c2.
15. Xu XJ, Tang YM, Liao C, Song H, Yang SL, Xu WQ, Shi SW, Zhao N: Inflammatory cytokine measurement quickly discriminates gram-negative from gram-positive bacteremia in pediatric hematology/oncology patients with septic shock. Intensive Care Med 2013,39(2):319-326. 10.1007/s00134-012-2752-4.
16. Gorschluter M, Mey U, Strehl J, Ziske C, Schepke M, Schmidt-Wolf IG, Sauerbruch T, Glasmacher A: Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 2005,75(1):1-13. 10.1111/j.1600-0609.2005.00442.x.
17. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009,48(5):503-535. 10.1086/596757.
18. Leroy O, Mira JP, Montravers P, Gangneux JP, Lortholary O: Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 2010,14(3):R98. 10.1186/cc9033.
19. Madureira A, Bergeron A, Lacroix C, Robin M, Rocha V, de Latour RP, Ferry C, Devergie A, Lapalu J, Gluckmana E, Socie G, Ghannoum M, Ribaud P: Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007,30(6):551-554. 10.1016/j.ijantimicag.2007.07.026.
20. Burghi G, Lemiale V, Seguin A, Lambert J, Lacroix C, Canet E, Moreau AS, Ribaud P, Schnell D, Mariotte E, Schlemmer B, Azoulay E: Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis. Intensive Care Med 2011,37(10):1605-1612. 10.1007/s00134-011-2344-8.
21. Sun HY, Singh N: Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis 2011,11(4):301-311. 10.1016/S1473-3099(10)70316-9.
22. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S: Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003,121(3):448-457. 10.1046/j.1365-2141.2003.04308.x.
23. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH: Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005,41(5):654-659. 10.1086/432470.
24. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH, Munoz P, Cristini F, Andoniadou A, Viale P, Rocca GD, Roilides E, Sganga G, Walsh TJ, Tascini C, Tumbarello M, Menichetti F, Righi E, Eckmann C, Viscoli C, Shorr AF, Leroy O, Petrikos G, De Rosa FG: A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 2013,39(12):2092-2106. 10.1007/s00134-013-3109-3.
25. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C: The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010,14(6):R222. 10.1186/cc9365.
26. Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, Shields RM, Cheng S, Mitsani D, Vadnerkar A, Silveira FP, Kleiboeker SB, Clancy CJ: Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012,54(9):1240-1248. 10.1093/cid/cis200.
27. McMullan R, Metwally L, Coyle PV, Hedderwick S, McCloskey B, O'Neill HJ, Patterson CC, Thompson G, Webb CH, Hay RJ: A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008,46(6):890-896. 10.1086/528690.
28. Mokart D, Slehofer G, Lambert J, Sannini A, Chow-Chine L, Brun JP, Berger P, Duran S, Faucher M, Blache JL, Saillard C, Vey N, Leone M: De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med 2014,40(1):41-49. 10.1007/s00134-013-3148-9.
29. Bassetti M, Paiva JA, Masterton RG: The case for de-escalation in antimicrobial therapy: time to change our strategy in the management of septic shock? Intensive Care Med 2014,40(2):284-285. 10.1007/s00134-013-3166-7.
30. Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernandez-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Marquez-Vacaro JA: De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014,40(1):32-40. 10.1007/s00134-013-3077-7.
31. Azoulay E, Schlemmer B: Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med 2006,32(6):808-822. 10.1007/s00134-006-0129-2.
32. Mokart D, Lambert J, Schnell D, Fouche L, Rabbat A, Kouatchet A, Lemiale V, Vincent F, Lengline E, Bruneel F, Pene F, Chevret S, Azoulay E: Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma 2013,54(8):1724-1729. 10.3109/10428194.2012.753446.
33. Schnell D, Mayaux J, Lambert J, Roux A, Moreau AS, Zafrani L, Canet E, Lemiale V, Darmon M, Azoulay E: Clinical assessment for identifying causes of acute respiratory failure in cancer patients. Eur Respir J 2013,42(2):435-443. 10.1183/09031936.00122512.
34. Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A, Kouatchet A, Vincent F, Gruson D, Bruneel F, Epinette-Branche G, Lafabrie A, Hamidfar-Roy R, Cracco C, Renard B, Tonnelier JM, Blot F, Chevret S, Schlemmer B: Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med 2010,182(8):1038-1046. 10.1164/rccm.201001-0018OC.
35. Navigante AH, Cerchietti LC, Costantini P, Salgado H, Castro MA, Lutteral MA, Cabalar ME: Conventional chest radiography in the initial assessment of adult cancer patients with fever and neutropenia. Cancer Control 2002,9(4):346-351.
36. Oude Nijhuis CS, Gietema JA, Vellenga E, Daenen SM, De Bont ES, Kamps WA, Groen HJ, van der Jagt EJ, van der Graaf WT: Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. Eur J Cancer 2003,39(17):2495-2498. 10.1016/j.ejca.2003.06.002.
37. Heussel CP, Kauczor HU, Heussel GE, Fischer B, Begrich M, Mildenberger P, Thelen M: Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999,17(3):796-805.
38. Caillot D, Latrabe V, Thiebaut A, Herbrecht R, De Botton S, Pigneux A, Monchecourt F, Mahi L, Alfandari S, Couaillier JF: Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol 2010,74(3):e172-175. 10.1016/j.ejrad.2009.05.058.
39. Heussel CP, Kauczor HU, Ullmann AJ: Pneumonia in neutropenic patients. Eur Radiol 2004,14(2):256-271. 10.1007/s00330-003-1985-6.
40. Georgiadou SP, Kontoyiannis DP: Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis? J Infect 2012,65(3):262-268. 10.1016/j.jinf.2012.05.001.
41. Shorr AF, Susla GM, O'Grady NP: Pulmonary infiltrates in the non-HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes. Chest 2004,125(1):260-271. 10.1378/chest.125.1.260.
42. Maschmeyer G, Braveny I: Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 2000,19(12):915-925. 10.1007/s100960000410.
43. Molina R, Bernal T, Borges M, Zaragoza R, Bonastre J, Granada RM, Rodriguez-Borregan JC, Nunez K, Seijas I, Ayestaran I, Albaiceta GM: Ventilatory support in critically ill hematology patients with respiratory failure. Crit Care 2012,16(4):R133. 10.1186/cc11438.
44. Adda M, Coquet I, Darmon M, Thiery G, Schlemmer B, Azoulay E: Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Crit Care Med 2008,36(10):2766-2772. 10.1097/CCM.0b013e31818699f6.
45. Azoulay E, Lemiale V: Non-invasive mechanical ventilation in hematology patients with hypoxemic acute respiratory failure: a false belief? Bone Marrow Transplant 2012,47(4):469-472. 10.1038/bmt.2011.232.
46. Azoulay E, Darmon M, Delclaux C, Fieux F, Bornstain C, Moreau D, Attalah H, Le Gall JR, Schlemmer B: Deterioration of previous acute lung injury during neutropenia recovery. Crit Care Med 2002,30(4):781-786. 10.1097/00003246-200204000-00010.
47. Azoulay E, Darmon M: Acute respiratory distress syndrome during neutropenia recovery. Crit Care 2010,14(1):114. 10.1186/cc8198.
48. Rhee CK, Kang JY, Kim YH, Kim JW, Yoon HK, Kim SC, Kwon SS, Kim YK, Kim KH, Moon HS, Park SH, Kim HJ, Lee S, Song JS: Risk factors for acute respiratory distress syndrome during neutropenia recovery in patients with hematologic malignancies. Crit Care 2009,13(6):R173. 10.1186/cc8149.
49. Raad I, Hanna H, Maki D: Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 2007,7(10):645-657. 10.1016/S1473-3099(07)70235-9.
50. Nesher L, Rolston KV: Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis 2013,56(5):711-717. 10.1093/cid/cis998.
51. Badgwell BD, Cormier JN, Wray CJ, Borthakur G, Qiao W, Rolston KV, Pollock RE: Challenges in surgical management of abdominal pain in the neutropenic cancer patient. Ann Surg 2008,248(1):104-109. 10.1097/SLA.0b013e3181724fe5.
52. Morcos B, Amarin R, Abu Sba A, Al-Ramahi R, Abu Alrub Z, Salhab M: Contemporary management of perianal conditions in febrile neutropenic patients. Eur J Surg Oncol 2013,39(4):404-407. 10.1016/j.ejso.2013.01.001.
53. Schnell D, Besset S, Lengline E, Maziers N, Zafrani L, Reuter D, Moreau AS, Canet E, Lemiale V, Azoulay E: Impact of a recent chemotherapy on the duration and intensity of the norepinephrine support during septic shock. Shock 2013,39(2):138-143. 10.1097/SHK.0b013e3182810a0f.
54. Lehrnbecher T, Welte K: Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002,116(1):28-56. 10.1046/j.1365-2141.2002.03230.x.
55. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005,23(18):4198-4214. 10.1200/JCO.2005.05.645.
56. Gruson D, Hilbert G, Vargas F, Valentino R, Chene G, Boiron JM, Reiffers J, Gbikpi-Benissan G, Cardinaud JP: Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients. Crit Care Med 2000,28(9):3155-3160. 10.1097/00003246-200009000-00005.
57. Karlin L, Darmon M, Thiery G, Ciroldi M, de Miranda S, Lefebvre A, Schlemmer B, Azoulay E: Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone Marrow Transplant 2005,36(3):245-250. 10.1038/sj.bmt.1705037.
58. Stanworth SJ, Massey E, Hyde C, Brunskill S, Lucas G, Navarrete C, Marks DI: Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2005, 3:CD005339.
59. Cherif H, Axdorph U, Kalin M, Bjorkholm M: Clinical experience of granulocyte transfusion in the management of neutropenic patients with haematological malignancies and severe infection. Scand J Infect Dis 2013,45(2):112-116. 10.3109/00365548.2012.714906.
60. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, Ubelacker R, Buchheidt D, Behre G, Hiddemann W, Schiel X: IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 2006,34(5):1319-1325. 10.1097/01.CCM.0000215452.84291.C6.
61. Kanamaru A, Tatsumi Y: Microbiological data for patients with febrile neutropenia. Clin Infect Dis 2004,39(Suppl 1):S7-S10.
62. Irfan S, Idrees F, Mehraj V, Habib F, Adil S, Hasan R: Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 2008, 8:80. 10.1186/1471-2334-8-80.
63. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T: Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007,51(6):1987-1994. 10.1128/AAC.01509-06.
64. Gudiol C, Bodro M, Simonetti A, Tubau F, Gonzalez-Barca E, Cisnal M, Domingo-Domenech E, Jimenez L, Carratala J: Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013,19(5):474-479. 10.1111/j.1469-0691.2012.03879.x.
65. Cuzon G, Naas T, Nordmann P: [KPC carbapenemases: what is at stake in clinical microbiology?]. Pathol Biol (Paris) 2010,58(1):39-45. 10.1016/j.patbio.2009.07.026.
66. Chemaly RF, Hanmod SS, Jiang Y, Rathod DB, Mulanovich V, Adachi JA, Rolston KV, Raad II, Hachem RY: Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 2009,88(4):211-220. 10.1097/MD.0b013e3181af01fc.
67. Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, Signorini L, Re A, Carosi G, Rossi G: Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008,61(3):721-728. 10.1093/jac/dkm514.
68. Herrero IA, Issa NC, Patel R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002,346(11):867-869. 10.1056/NEJM200203143461121.
69. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ: In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002,46(6):1723-1727. 10.1128/AAC.46.6.1723-1727.2002.
70. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003,41(8):3623-3626. 10.1128/JCM.41.8.3623-3626.2003.
71. Karwa R, Wargo KA: Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother 2009,43(11):1818-1823. 10.1345/aph.1M218.
72. Krenova Z, Pavelka Z, Lokaj P, Skotakova J, Kocmanova I, Teyschl O, Kren L, Mudry P, Sterba J: Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-Hodgkin lymphoma using Efungumab and amphotericin B colloid dispersion. J Pediatr Hematol Oncol 2010,32(2):128-130. 10.1097/MPH.0b013e3181cb49a8.
73. Ostrosky-Zeichner L: Combination antifungal therapy: a critical review of the evidence. Clin Microbiol Infect 2008,14(Suppl 4):65-70.
74. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008,46(3):327-360. 10.1086/525258.